Loading clinical trials...
Loading clinical trials...
A PROSPECTIVE, RANDOMIZED,OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM- AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO -Β-LACTAMASE (MBL)
Conditions
Interventions
ATM-AVI
BAT
Locations
42
United States
Banner University Medical Center Tucson
Tucson, Arizona, United States
Hospital San Roque
Córdoba, Argentina
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
Hunan Province People's Hospital
Changsha, Hunan, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Start Date
December 25, 2020
Primary Completion Date
January 23, 2023
Completion Date
January 23, 2023
Last Updated
February 2, 2024
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions